Identifying subpopulations with distinct response to treatment using plasma biomarkers in acute heart failure: results from the PROTECT trial

Liu, L. C.Y. et al. (2017) Identifying subpopulations with distinct response to treatment using plasma biomarkers in acute heart failure: results from the PROTECT trial. Cardiovascular Drugs and Therapy, 31(3), pp. 281-293. (doi: 10.1007/s10557-017-6726-1) (PMID:28656542) (PMCID:PMC5550531)

[img]
Preview
Text
143308.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Background: Over the last 50 years, clinical trials of novel interventions for acute heart failure (AHF) have, with few exceptions, been neutral or shown harm. We hypothesize that this might be related to a differential response to pharmacological therapy. Methods: We studied the magnitude of treatment effect of rolofylline across clinical characteristics and plasma biomarkers in 2033 AHF patients and derived a biomarker-based responder sum score model. Treatment response was survival from all-cause mortality through day 180. Results: In the overall study population, rolofylline had no effect on mortality (HR 1.03, 95% CI 0.82–1.28, p = 0.808). We found no treatment interaction across clinical characteristics, but we found interactions between several biomarkers and rolofylline. The biomarker-based sum score model included TNF-R1α, ST2, WAP four-disulfide core domain protein HE4 (WAP-4C), and total cholesterol, and the score ranged between 0 and 4. In patients with score 4 (those with increased TNF-R1α, ST2, WAP-4C, and low total cholesterol), treatment with rolofylline was beneficial (HR 0.61, 95% CI 0.40–0.92, p = 0.019). In patients with score 0, treatment with rolofylline was harmful (HR 5.52, 95% CI 1.68–18.13, p = 0.005; treatment by score interaction p < 0.001). Internal validation estimated similar hazard ratio estimates (0 points: HR 5.56, 95% CI 5.27–7–5.87; 1 point: HR 1.31, 95% CI 1.25–1.33; 2 points: HR 0.75, 95% CI 0.74–0.76; 3 points: HR 1.13, 95% CI 1.11–1.15; 4 points, HR 0.61, 95% CI 0.61–0.62) compared to the original data. Conclusion: Biomarkers are superior to clinical characteristics to study treatment heterogeneity in acute heart failure.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Liu, L. C.Y., Valente, M. A.E., Postmus, D., O’Connor, C. M., Metra, M., Dittrich, H. C., Ponikowski, P., Teerlink, J. R., Cotter, G., Davison, B., Cleland, J. G.F., Givertz, M. M., Bloomfield, D. M., van Veldhuisen, D. J., Hillege, H. L., van der Meer, P., and Voors, A. A.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:Cardiovascular Drugs and Therapy
Publisher:Springer
ISSN:0920-3206
ISSN (Online):1573-7241
Published Online:27 June 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in Cardiovascular Drugs and Therapy 31(3):281-293
Publisher Policy:Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record